A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

NCT06952530 · tracked via the Priya Life Science India tracker

Sponsor

Eli Lilly and Company

Phase

Phase 3

Started

2025-04-30

Last updated

2026-05-29

Condition(s) studied

Hypertension

Investigational drug(s) / intervention(s)

OrforglipronPlacebo

Orforglipron: Administered orally

Placebo: placebo administered

Study summary

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * refer to the GZPL master protocol study for screening eligibility. Exclusion Criteria: * refer to the GZPL master protocol study for screening eligibility.

Primary outcome measure(s)

Change from Baseline in office Systolic Blood Pressure (SBP) — Baseline to Week 36

Trial sites (99)

Facility	City	Region
Elite Clinical Studies, LLC	Phoenix	Arizona
Valley Clinical Trials, Inc.	Covina	California
Valley Clinical Trials, Inc.	Northridge	California
Chase Medical Research, LLC	Waterbury	Connecticut
Excel Medical Clinical Trials	Boca Raton	Florida
Care Access - Brandon	Brandon	Florida
Northeast Research Institute - Downtown Office	Jacksonville	Florida
Peace River Cardiovascular Center	Port Charlotte	Florida
East-West Medical Research Institute	Honolulu	Hawaii
Sinai Hospital Of Baltimore	Baltimore	Maryland
Ascension Saint Agnes Heart Care	Baltimore	Maryland
Lucida Clinical Trials	New Bedford	Massachusetts
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division	Troy	Michigan
StudyMetrix Research	City of Saint Peters	Missouri
Excel Clinical Research, LLC	Las Vegas	Nevada
Palm Research Center Sunset	Las Vegas	Nevada
Rochester Clinical Research, LLC	Rochester	New York
Remington-Davis, Inc	Columbus	Ohio
Advanced Research Institute - Tigard	Tigard	Oregon
Care Access - Mauldin	Mauldin	South Carolina
Dallas Heart and Vascular Consultants, PA	Duncanville	Texas
Texas Institute of Cardiology, PA	McKinney	Texas
North Hills Family Medicine/North Hills Medical Research	North Richland Hills	Texas
Advanced Research Institute	Ogden	Utah
Carient Heart & Vascular - Manassas	Manassas	Virginia
Health Research of Hampton Roads, Inc.	Newport News	Virginia
National Clinical Research, Inc	Richmond	Virginia
Eastside Research Associates	Redmond	Washington
Instituto Médico Especializado (IME)	Buenos Aires	Argentina
CIPREC	Buenos Aires	Argentina
CIPREC	Buenos Aires	Argentina
CEMEDIC	Buenos Aires	Argentina
Instituto de Investigaciones Clínicas Córdoba	Córdoba	Argentina
Centro de Investigaciones Clínicas Baigorria	Granadero Baigorria	Argentina
INECO Neurociencias Oroño	Rosario	Argentina
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica	Rosario	Argentina
Santa Maria de la Salud Centro Medico	San Isidro	Argentina
Beijing Pinggu District Hospital	Beijing	China
China-Japan Union Hospital	Changchun	China
Changde First People's Hospital	Changde	China

+ 59 more sites — see the full list on the official registry below.

More Eli Lilly and Company trials in India

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) Recruiting

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) Active, not recruiting

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight Recruiting

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight Recruiting

A Study of Brenipatide in Adult Participants With Schizophrenia Recruiting

Other trials for the same condition

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease Recruiting

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) Active, not recruiting

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 Active, not recruiting

iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06952530 on ClinicalTrials.gov ↗ ← All trials in India